Choose License Type
The global wound debridement market was valued at USD 5.19 billion in 2019. In the case of casualties, the growing number of incidents and fire outbreaks is contributing to an increase. This, in turn, is stimulating the market's growth. In addition, the growth in diabetes-induced wounds due to the increasing prevalence of the disease provides the industry with an up thrust. In addition, the industry is fueled by the spiraling acceptance of debridement drugs and techniques to faster heal a wound.
The involvement of the wound's micro-organisms and toxins prevents healing and can contribute to infection. In order to facilitate regeneration, debridement extracts the dead or contaminated tissues from the wound. It is expected that increasing government and private organizations efforts to increase awareness of wound care services would work in favour of the market.
The increased frequency of ulcers is anticipated to further fuel business demand. As per the American Diabetes Association estimates, approximately 2.0 percent of the U.S. population was afflicted by diabetic ulcer in 2014. Similarly, every year about 600,000 people in the world are afflicted by venous ulcers.
Key segments of the global Wound Debridement market
Product Overview, 2018-2028 (USD Billion)
Method Overview, 2018-2028 (USD Billion)
Wound Type Overview, 2018-2028 (USD Billion)
Regional Overview, 2018-2028 (USD Billion)
Reasons for the study
What does the report include?
Who should buy this report?
In order to make a wound heal, debridement is the elimination of dead (necrotic) or contaminated skin tissue. The separation of foreign material from tissue is also performed. For wounds that are not getting better, the procedure is necessary. Usually, in the first step of regeneration, these wounds are stuck. The wound will re-start the healing process until bad tissue is extracted. Biological debridement uses sterile maggots, the common green bottle fly, from the genus Lucilia sericata. The procedure is also called larval therapy, debridement therapy for maggots, and biosurgery.
To prepare the wound bed for reepithelialization, debridement is known as a major component of wound care. In general, devitalized tissue and, in particular, necrotic tissue serve as a food supply for bacteria. Devitalized tissue often serves as a physical barrier to reepithelialization, avoiding the overt interaction of applied topical substances with the wound bed to provide their beneficial properties. Angiogenesis, development of granulation tissue, epidermal resurfacing, and normal extracellular matrix (ECM) formation are also avoided by necrotic tissue.
The global market is segmented on the basis of product, Method, Wound Type. The product segment is further broken down to gels, ointment & creams, surgical devices, medical gauzes, ultrasonic devices, others. The method segment is further broken down into autolytic, enzymatic, surgical, mechanical, others. The Wound Type segment is broken down into pressure ulcers, diabetic foot ulcers, venous leg ulcers, burn wound, others.
In 2019, gels dominated the global market on account of its highest owing to advantages such as less inflammation, minimal bleeding and easily scraping necrotic tissues without risking infection. Due to its capacity to destroy micro-organisms at the wound site without destroying blood vessels, ultrasonic devices have been projected to be the fastest-growing market. The ultrasonic system also separates non-viable tissues and viable tissues without impacting healthy ones and extracts only non-viable tissues.
On the basis of region, the global market is classified into North America, Europe, Asia Pacific, Central & South America, and Middle East and Africa. As of 2018, North America accounted for the dominant share compared to other regional markets, and is projected to retain its domination throughout the forecast period. The presence of developed medical facilities and growing patient awareness can be attributed to the region's growth, combined with increasing disposable income and the increasing demand for quality medical products and services.
During the forecast era, Asia Pacific is poised to experience lucrative growth. The development of the regional market is caused by booming economies, infrastructure improvement initiatives, strong unmet needs of the vast population, and the availability of skilled labour. It is also projected that Europe will retain a sizeable market share over the same time.
Key players in the market include Acelity L.P. Inc, Smith & Nephew, B. Braun Melsungen AG, ConvaTec Group, Coloplast , Paul Hartmann, Mölnlycke Health Care, Lohmann & Rauscher, Medline Industries, and many more. These players are engaged in numerous corporate strategies such as alliances, geographic growth, expansion of the service offering, mergers, and acquisitions in order to achieve a higher market share. Acelity L.P. Inc., for example, purchased Crawford Healthcare in June 2018 to broaden its advanced wound dressing portfolio and further improve its position as the world leader in advanced wound treatment.
The global wound debridement market was valued at USD 5.19 billion in 2019. In the case of casualties, the growing number of incidents and fire outbreaks is contributing to an increase. This, in turn, is stimulating the market's growth. In addition, the growth in diabetes-induced wounds due to the increasing prevalence of the disease provides the industry with an up thrust. In addition, the industry is fueled by the spiraling acceptance of debridement drugs and techniques to faster heal a wound.
The involvement of the wound's micro-organisms and toxins prevents healing and can contribute to infection. In order to facilitate regeneration, debridement extracts the dead or contaminated tissues from the wound. It is expected that increasing government and private organizations efforts to increase awareness of wound care services would work in favour of the market.
The increased frequency of ulcers is anticipated to further fuel business demand. As per the American Diabetes Association estimates, approximately 2.0 percent of the U.S. population was afflicted by diabetic ulcer in 2014. Similarly, every year about 600,000 people in the world are afflicted by venous ulcers.
Key segments of the global Wound Debridement market
Product Overview, 2018-2028 (USD Billion)
Method Overview, 2018-2028 (USD Billion)
Wound Type Overview, 2018-2028 (USD Billion)
Regional Overview, 2018-2028 (USD Billion)
Reasons for the study
What does the report include?
Who should buy this report?
1. Introduction
1.1. Introduction
1.2. Market Definition and Scope
1.3. Units, Currency, Conversions and Years Considered
1.4. Key Stakeholders
1.5. Key Questions Answered
2. Research Methodology
2.1. Introduction
2.2. Data Capture Sources
2.3. Market Size Estimation
2.4. Market Forecast
2.5. Data Triangulation
2.6. Assumptions and Limitations
3. Market Outlook
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. Porter’s Five Forces Analysis
3.4. COVID-19 impact analysis
4. Wound Debridement Market by Product, 2018-2028 (USD Million)
4.1. Gels
4.2. Ointment & creams
4.3. Surgical devices
4.4. Medical gauzes
4.5. Ultrasonic devices
4.6. Others
5. Wound Debridement Market by Method, 2018-2028 (USD Million)
5.1. Autolytic
5.2. Enzymatic
5.3. Surgical
5.4. Mechanical
5.5. Others
6. Wound Debridement Market by Wound Type, 2018-2028 (USD Million)
6.1. Pressure ulcers
6.2. Diabetic foot ulcers
6.3. Venous leg ulcers
6.4. Burn wound
6.5. Others
7. Wound Debridement Market by Region 2018-2028 (USD Million)
7.1. North America
7.1.1. U.S.
7.1.2. Canada
7.2. Europe
7.2.1. UK
7.2.2. Germany
7.2.3. France
7.2.4. Rest of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. Japan
7.3.3. India
7.3.4. Rest of APAC
7.4. Latin America
7.4.1. Brazil
7.4.2. Mexico
7.4.3. Rest of Latin America
7.5. Middle East & Africa
8. Competitive Landscape
8.1. Company Ranking
8.2. Market Share Analysis
8.3. Strategic Initiatives
8.3.1. Mergers & Acquisitions
8.3.2. New Type Launch
8.3.3. Investments
8.3.4. Expansion
8.3.5. Others
9. Company Profiles
9.1. Acelity L.P. Inc
9.1.1. Overview
9.1.2. Types Portfolio
9.1.3. Recent Initiatives
9.1.4. Company Financials
9.2. Smith & Nephew
9.3. B. Braun Melsungen AG
9.4. ConvaTec Group
9.5. Coloplast
9.6. Paul Hartmann
9.7. Mölnlycke Health Care
9.8. Lohmann & Rauscher
9.9. Medline Industries
10. Appendix
10.1. Primary Research Approach
10.1.1. Primary Interview Participants
10.1.2. Primary Interview Summary
10.2. Questionnaire
10.3. Related Reports
10.3.1. Published
10.3.2. Upcoming